Geron posts presentation on real-world imetelstat outcomes in heavily pretreated lower-risk MDS patients

Geron Corporation

Geron Corporation

GERN

0.00
  • Geron published a real-world outcomes report on imetelstat in heavily pretreated lower-risk MDS patients treated at Moffitt Cancer Center.
  • RBC transfusion independence longer than 8 weeks reached 37.5% (15 of 40); median response duration was 185 days; 7 responses remained ongoing.
  • Exploratory modeling flagged baseline platelet count, ASXL1 mutation status, and IPSS-R at diagnosis as key response predictors.
  • Grade 3/4 neutropenia ran 35% after cycle 1; 22.5% after cycle 2; no febrile neutropenia reported.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.